At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses the selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta isoform (P110?), idelalisib, in the management of haematological malignancies, including lymphoma and chronic lymphocytic leukaemia (CLL). Idelalisib is considered in combination with other therapies to enhance efficacy endpoints.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content